Literature DB >> 11831608

Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.

Ronald Kurstin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11831608

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  11 in total

Review 1.  Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

2.  Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.

Authors:  Franck Lebrin; Samly Srun; Karine Raymond; Sabrina Martin; Stieneke van den Brink; Catarina Freitas; Christiane Bréant; Thomas Mathivet; Bruno Larrivée; Jean-Léon Thomas; Helen M Arthur; Cornelis J J Westermann; Frans Disch; Johannes J Mager; Repke J Snijder; Anne Eichmann; Christine L Mummery
Journal:  Nat Med       Date:  2010-04-04       Impact factor: 53.440

Review 3.  Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.

Authors:  Juergen Bauditz; Herbert Lochs
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

Review 4.  Emerging role of thalidomide in the treatment of gastrointestinal bleeding.

Authors:  Michael McFarlane; Lauren O'Flynn; Rachel Ventre; Benjamin R Disney
Journal:  Frontline Gastroenterol       Date:  2017-11-02

5.  Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.

Authors:  Sung Ok Park; Mamta Wankhede; Young Jae Lee; Eun-Jung Choi; Naime Fliess; Se-Woon Choe; Seh-Hoon Oh; Glenn Walter; Mohan K Raizada; Brian S Sorg; S Paul Oh
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

Review 6.  Effective treatment of gastrointestinal bleeding with thalidomide--Chances and limitations.

Authors:  Juergen Bauditz
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

7.  Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.

Authors:  Rosangela Invernizzi; Federica Quaglia; Catherine Klersy; Fabio Pagella; Federica Ornati; Francesco Chu; Elina Matti; Giuseppe Spinozzi; Sara Plumitallo; Pierangela Grignani; Carla Olivieri; Raffaella Bastia; Francesca Bellistri; Cesare Danesino; Marco Benazzo; Carlo L Balduini
Journal:  Lancet Haematol       Date:  2015-10-27       Impact factor: 18.959

8.  A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab.

Authors:  Ahmad Amanzada; Gwen-Jana Töppler; Silke Cameron; Harald Schwörer; Giuliano Ramadori
Journal:  Case Rep Oncol       Date:  2010-12-11

Review 9.  Therapeutic effects of thalidomide in hematologic disorders: a review.

Authors:  Miao Xu; Yu Hou; Lei Sheng; Jun Peng
Journal:  Front Med       Date:  2013-07-15       Impact factor: 9.927

Review 10.  Pericytes as targets in hereditary hemorrhagic telangiectasia.

Authors:  Jérémy Thalgott; Damien Dos-Santos-Luis; Franck Lebrin
Journal:  Front Genet       Date:  2015-02-13       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.